RESUMEN
Technical improvements as well as various strategies for error detection and error prevention have made intensive care medicine and anesthesiology a safe medical specialty. Due to the introduction of "Patient safety in the ICU: the Vienna declaration" of the European Society of Intensive Care Medicine (ESICM) from October 2009 and the "Helsinki declaration on patient safety" of the European Society of Anaesthesiology (ESA) and the European Board of Anaesthesiology (EBA) from June 2010, there are now specific recommendations for all hospitals in Europe concerning the safety measures that are considered to be of essential importance. Many of today's well-known safety strategies have been originally developed in non-medical environments, as for instance civil aviation. Such high reliability organizations may serve as examples in the medical domain. Critical incident reporting systems, crisis resource management and checklists, e.g. the World Health Organization (WHO) checklist, are safety approaches of this kind. In addition to these, standardized drug labelling, hand disinfection, techniques for patient handover and simulation-based training have been exemplarily selected for this article as measures that can increase patient safety.
Asunto(s)
Anestesiología , Cuidados Críticos , Seguridad del Paciente , Mejoramiento de la Calidad , Lista de Verificación , Alemania , Adhesión a Directriz , Humanos , Errores Médicos/prevención & control , Medición de RiesgoRESUMEN
OBJECTIVE: This double-blind, prospective, randomized, controlled trial examined the effects of thoracic epidural block and intravenous clonidine and opioid treatment on the postoperative Th1/Th2 cytokine ratio after lung surgery. The primary endpoint was the interferon γ (IFN-γ; Th1 cytokine)/interleukin 4 (IL-4; Th2 cytokine) ratio. Secondary endpoints were reductions in pain and incidence of pneumonia. METHODS: Sixty patients were randomized into three groups to receive remifentanil intravenously (remifentanil group, n=20), remifentanil and clonidine intravenously (clonidine group, n=20), or ropivacaine epidurally (ropivacaine group, n=20). Pain was assessed using a numerical rating scale (NRS). Cytokines were measured using a cytometric bead array. RESULTS: Patients in the ropivacaine group (thoracic epidural block) had a significantly lower IFN-γ/IL-4 ratio at the end of surgery than those in the remifentanil group and clonidine group. There were no significant between-group differences in the IFN-γ/IL-4 ratio at other time-points. There were no differences in NRS scores at any time-point. No patient developed pneumonia. CONCLUSION: Intraoperative thoracic epidural block decreased the IFN-γ/IL-4 ratio immediately after lung surgery, indicating less inflammatory stimulation during surgery.
Asunto(s)
Pulmón/inmunología , Pulmón/cirugía , Bloqueo Nervioso , Atención Perioperativa , Anciano , Amidas/administración & dosificación , Amidas/farmacología , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/farmacología , Anestésicos Locales/administración & dosificación , Anestésicos Locales/farmacología , Clonidina/administración & dosificación , Clonidina/farmacología , Femenino , Hemodinámica/efectos de los fármacos , Humanos , Inyecciones Epidurales , Inyecciones Intravenosas , Interferón gamma/metabolismo , Interleucina-4/metabolismo , Pulmón/fisiopatología , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Piperidinas/administración & dosificación , Piperidinas/farmacología , Remifentanilo , Ropivacaína , Resultado del TratamientoRESUMEN
BACKGROUND: This study investigates whether long-term treatment with an angiotensin-converting enzyme inhibitor (ACEI) impairs the haemodynamic regulation during total intravenous anaesthesia (TIVA) for minor surgery. METHODS: In a prospective, two-armed observational study, 36 patients undergoing TIVA for minor surgery were studied. Seventeen were taking ACEIs regularly but no other antihypertensive medication (ACEI group); 19 patients without any cardiovascular medication served as controls (non-ACEI group). Haemodynamic variables were measured every minute during induction and every 5 min during surgery. The plasma levels of renin, angiotensin II, vasopressin and catecholamines were measured before and 18 min after the induction of anaesthesia. RESULTS: The mean arterial pressure decreased to the same extent in both the groups during the induction of TIVA. There were also no differences between the groups regarding the heart rate, systolic and diastolic arterial pressure, as well as the use of vasoconstrictors, and fluids during induction and throughout surgery. In the ACEI group, the plasma renin concentration was higher at baseline and after the induction of anaesthesia presumably due to the interruption of the negative renin-angiotensin feedback loop (P<0.05). Angiotensin II increased only in the non-ACEI group (6.2 ± 2.2 before vs. 9.6 ± 3.5 pg/ml after induction; P<0.05). In both groups, the plasma norepinephrine concentration decreased after the induction of TIVA (P<0.05). Plasma vasopressin and plasma epinephrine concentrations did not change in either group. CONCLUSION: Long-term ACEI treatment does not further aggravate the blood pressure decrease under TIVA during minor surgery, provided the induction procedure is slow, the patient is kept well hydrated and vasoconstrictors are promptly applied.
Asunto(s)
Anestesia Intravenosa , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Antihipertensivos/farmacología , Presión Sanguínea/efectos de los fármacos , Procedimientos Quirúrgicos Menores , Anciano , Angiotensina II/sangre , Catecolaminas/sangre , Femenino , Fluidoterapia/estadística & datos numéricos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Monitoreo Intraoperatorio , Estudios Prospectivos , Renina/sangre , Sistema Renina-Angiotensina/efectos de los fármacos , Tamaño de la Muestra , Resultado del Tratamiento , Vasoconstrictores/uso terapéutico , Vasopresinas/sangreRESUMEN
Expert panel consensus was used to develop evidence-based process indicators that were independent risk factors for the main clinical outcome parameters of length of stay in the intensive care unit (ICU) and mortality. In a retrospective, matched data analysis of patients from five ICUs at a tertiary university hospital, agreed process indicators (sedation monitoring, pain monitoring, mean arterial pressure [MAP] >or= 60 mmHg, tidal volume [TV] Asunto(s)
Cuidados Críticos/normas
, Unidades de Cuidados Intensivos
, Tiempo de Internación
, Anciano
, Analgesia
, Estudios de Casos y Controles
, Estudios de Cohortes
, Sedación Profunda
, Humanos
, Persona de Mediana Edad
, Dimensión del Dolor
, Estudios Prospectivos
, Estudios Retrospectivos
RESUMEN
BACKGROUND AND OBJECTIVE: Four percent gelatine is an alkaline compound due to NH2 groups, whereas 6% hydroxyethyl starch 130/0.4 (HES130) has acidic features. We investigated whether these solutions lead to differences in acid-base balance in pigs during acidaemia and correction of pH. METHODS: Anaesthetized pigs were randomized to HES130 or gelatine infusion (n = 5 per group). Animals received acid infusion (0.4 M solution of lactic acid and HCl diluted in normal saline) and low tidal volume ventilation (6-7 mL kg(-1), PaCO2 of 80-85 mmHg, pH 7.19-7.24). Measurements were made before and after induction of acidaemia, before and after correction of pH with haemofiltration (continuous venovenous haemofiltration) and tris-hydroxymethylaminomethane infusion. We measured parameters describing acid-base balance according to Stewart's approach, ketone body formation, oxygen delivery, haemodynamics, diuresis and urinary pH. RESULTS: Acid-base balance did not differ significantly between the groups. In HES130-treated pigs, the haemodilution-based drop of haemoglobin (1.4 +/- 1.0 g dL(-1), median +/- SD) was paralleled by an increase in the cardiac output (0.5 +/- 0.4 L min(-1). Lacking increases in cardiac output, gelatine-treated pigs demonstrated a reduction in oxygen delivery (149.4 +/- 106.0 mL min(-1)). Tris-hydroxymethylaminomethane volumes required for pH titration to desired values were significantly higher in the gelatine group (0.7 +/- 0.1 mL kg(-1) h(-1) vs. HES130: 0.5 +/- 0.2 mL kg(-1) h(-1)). CONCLUSION: The buffer capacity of gelatine did not lead to favourable differences in acid-base balance in comparison to HES130.
Asunto(s)
Acidosis/terapia , Tampones (Química) , Gelatina/química , Derivados de Hidroxietil Almidón/química , Acidosis/patología , Animales , Coloides/química , Hemodinámica , Hemofiltración , Concentración de Iones de Hidrógeno , Hipercapnia , Ácido Láctico/metabolismo , Masculino , Modelos Animales , Oxígeno/metabolismo , PorcinosRESUMEN
Despite substantial improvement in the management of patients with aneurysmal subarachnoid hemorrhage (SAH), including early aneurysm occlusion by endovascular techniques and surgical procedures, a significant percentage of patients with SAH still experience serious sequelae of neurological or cognitive deficits as a result of primary hemorrhage and/or secondary brain damage. Available neuromonitoring methods for early recognition of ischemia include, among others, measurement of brain tissue O(2) partial pressure, brain metabolism with microdialysis and monitoring of regional blood flow. The triple-H therapy (arterial hypertension, hypervolemia and hemodilution) is the treatment of choice of a symptomatic vasospasm and leads to an enduring recession of ischemic symptoms, if initiated early after the onset of a vasospasm-linked ischemic neurological deficit. Further promising therapy approaches are the administration of highly selective ET(A) receptor antagonists and intracisternal administration of vasodilators in depot form. This review summarizes the major neurological and non-neurological complications following aneurysm occlusion. Possible neuromonitoring techniques to improve diagnosis and therapy for treatment of symptomatic vasospasm as well as extracranial complications are discussed.
Asunto(s)
Hemorragia Subaracnoidea/complicaciones , Hemorragia Subaracnoidea/fisiopatología , Depresión de Propagación Cortical , Cuidados Críticos , Humanos , Hidrocefalia/etiología , Hiperglucemia , Hipertensión Intracraneal/etiología , Enfermedades Pulmonares/etiología , Enfermedades del Sistema Nervioso/etiología , Procedimientos Neuroquirúrgicos , Hemorragia Subaracnoidea/epidemiología , Hemorragia Subaracnoidea/terapia , Vasoespasmo Intracraneal/etiología , Desequilibrio Hidroelectrolítico/etiologíaRESUMEN
Awake craniotomy in tumor and epilepsy surgery or for the implantation of electrodes for deep brain stimulation requires specific anesthesiological strategies. Propofol allows for quick emergence and has little effect on the respiratory function of the usually spontaneously breathing patient. Pain control may be instituted by hemiscalp block for trepanation or local infiltration for deep brain electrode implantation. In addition, low dose remifentanil is recommended for trepanation (i.e. tumor or epilepsy surgery). The airway may be secured by an ordinary Magill tube placed transnasally with its tip underneath the epiglottis. To protect the patient against vomiting an adequate antiemetic prophylaxis is required.
Asunto(s)
Anestesia , Craneotomía , Vigilia , Anestesia General , Anestesia Intravenosa , Anestésicos Intravenosos , Neoplasias Encefálicas/cirugía , Sedación Consciente , Estimulación Encefálica Profunda , Electrodos Implantados , Epilepsia/cirugía , Humanos , Bloqueo Nervioso , Propofol , Implantación de Prótesis , Respiración ArtificialRESUMEN
Hepatorenal syndrome (HRS) is defined as the development of renal insufficiency in chronic liver disease with portal hypertension when other causes of functional renal failure are excluded. Incidence in patients with refractory ascites is 8%, with an overall incidence of renal failure in end stage liver disease being 75%. HRS is predictive for the prognosis of end stage liver failure but its pathogenesis is complex and currently not fully understood.
Asunto(s)
Síndrome Hepatorrenal/patología , Diagnóstico Diferencial , Síndrome Hepatorrenal/diagnóstico , Síndrome Hepatorrenal/fisiopatología , Síndrome Hepatorrenal/terapia , Humanos , Trasplante de Riñón , Trasplante de Hígado , Derivación Portosistémica Quirúrgica , Sistema Renina-Angiotensina/fisiología , Terminología como AsuntoRESUMEN
Blood gas analysis provides valuable information about both the extracellular acid-base status and gas exchange. A blood gas analyzer measures pH, partial pressure of oxygen(pO(2)), partial pressure of carbon dioxide (pCO(2)), O(2) saturation, and hemoglobin concentration. A number of calculated parameters can be derived from these direct measurements such as bicarbonate concentration, base excess, oxygen content, etc. This contribution introduces the basic technical aspects of a blood gas analyzer and then describes some of the parameters that facilitate evaluation of the acid-base status and the oxygenation status of the blood. Finally, proper sampling and handling of blood gas samples is addressed.
Asunto(s)
Análisis de los Gases de la Sangre , Análisis de los Gases de la Sangre/instrumentación , Análisis de los Gases de la Sangre/normas , Dióxido de Carbono/sangre , Humanos , Hipoxia/sangre , Hipoxia/diagnóstico , Monitoreo Intraoperatorio , Oxígeno/sangre , Equilibrio Hidroelectrolítico/fisiologíaRESUMEN
Evidence indicates that nitric oxide (NO) suppresses myocardial oxygen consumption (MVO(2)) and regulates myocardial substrate oxidation, however data from in vivo and isolated heart preparations are conflicting. In addition, cardiac endothelin (ET-1) release has been shown to increase with inhibition of NO synthase (NOS), however the effects of ET-1 on myocardial energetics is not clear. We employed the isolated rat heart model to assess the role of NO and ET-1 on myocardial function and metabolism. Oxidation of glucose and FFA was measured using [U-(14)C]glucose and [9,10-(3)H]palmitate. NOS inhibition with N(G)-methyl-L-arginine acetate salt (L-NMMA, 50 microM), resulted in an increase in MVO(2) at a given rate of myocardial external workload, and no change in myocardial glucose or FFA oxidation. ET-1 (25 pM), which caused coronary vasoconstriction similar to that produced by L-NMMA, also increased MVO(2) without an effect on cardiac workload, or substrate oxidation, suggesting a role for ET-I in the regulation of myocardial energetics. We assessed also the effect of ET(A)/ET(B) receptor blockade (tezosentan; 5 nM) on MVO(2) and glucose and FFA oxidation and observed no effect, suggesting that basal ET-1 production does not play a role in regulating MVO2 or substrate selection. In conclusion, inhibition of NOS or the addition of ET-1 resulted in an increase in MVO2, but did not affect glucose or FFA oxidation.
Asunto(s)
Endotelina-1/metabolismo , Glucosa/metabolismo , Miocardio/metabolismo , Óxido Nítrico Sintasa/antagonistas & inhibidores , Consumo de Oxígeno/efectos de los fármacos , Palmitatos/metabolismo , Animales , Circulación Coronaria/efectos de los fármacos , Diástole/efectos de los fármacos , Diástole/fisiología , Antagonistas de los Receptores de la Endotelina A , Antagonistas de los Receptores de la Endotelina B , Endotelina-1/farmacología , Glucosa/química , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Ventrículos Cardíacos/efectos de los fármacos , Ácido Láctico/química , Ácido Láctico/metabolismo , Masculino , Miocardio/química , Palmitatos/química , Piridinas/administración & dosificación , Piridinas/farmacocinética , Piridinas/farmacología , Ratas , Receptor de Endotelina A/fisiología , Receptor de Endotelina B/fisiología , Tetrazoles/administración & dosificación , Tetrazoles/farmacocinética , Tetrazoles/farmacología , Tritio , Función Ventricular , Agua/metabolismo , omega-N-Metilarginina/farmacologíaRESUMEN
AIM: This study investigates angiotensin II and endothelin-1 mediated mechanisms involved in the haemodynamic, hormonal, and renal response towards acute hypotensive haemorrhage. METHODS: Conscious dogs were pre-treated with angiotensin II type 1 (AT1) and/or endothelin-A (ETA) receptor blockers or not. Protocol 1: After a 60-min baseline period, 25% of the dog's blood was rapidly withdrawn. The blood was retransfused 60 min later and data recorded for another hour. Protocol 2: Likewise, but preceded by AT1 blockade with i.v. Losartan. Protocol 3: Likewise, but preceded by ETA blockade with i.v. ABT-627. Protocol 4: Likewise, but with combined AT1 plus ETA blockade. RESULTS: In controls, haemorrhage decreased mean arterial pressure (MAP) by approximately 25%, cardiac output by approximately 40%, and urine volume by approximately 60%, increased angiotensin II (3.1-fold), endothelin-1 (1.13-fold), vasopressin (116-fold), and adrenaline concentrations (3.2-fold). Glomerular filtration rate and noradrenaline concentrations remained unchanged. During AT1 blockade, the MAP decrease was exaggerated (-40%) and glomerular filtration rate fell. During ETA blockade, noradrenaline increased after haemorrhage instead of adrenaline, and the MAP recovery after retransfusion was blunted. The decrease in cardiac output was similar in all protocols. CONCLUSIONS: Angiotensin II is more important than endothelin-1 for the short-term regulation of MAP and glomerular filtration rate after haemorrhage, whereas endothelin-1 seems necessary for complete MAP recovery after retransfusion. After haemorrhage, endothelin-1 seems to facilitate adrenaline release and to blunt noradrenaline release. Haemorrhage-induced compensatory mechanisms maintain blood flow more effectively than blood pressure, as the decrease in cardiac output--but not MAP--was similar in all protocols.
Asunto(s)
Antihipertensivos/farmacología , Hemodinámica/efectos de los fármacos , Hemorragia/metabolismo , Losartán/farmacología , Pirrolidinas/farmacología , Angiotensina II/análisis , Animales , Atrasentán , Presión Sanguínea/efectos de los fármacos , Transfusión Sanguínea , Gasto Cardíaco/efectos de los fármacos , Perros , Endotelina-1/análisis , Epinefrina/análisis , Femenino , Tasa de Filtración Glomerular/efectos de los fármacos , Norepinefrina/análisis , Receptor de Endotelina A , Volumen Sistólico/efectos de los fármacos , Orina , Resistencia Vascular/efectos de los fármacos , Vasopresinas/análisisAsunto(s)
Anestesia , Craneotomía , Monitoreo Intraoperatorio , Vigilia , Humanos , Medicación Preanestésica , Medición de RiesgoRESUMEN
BACKGROUND: This study investigates whether long-term treatment with an angiotensin converting enzyme inhibitor (ACEI) impairs the hemodynamic regulation during the early phase of spinal anaesthesia. METHODS: Forty-two patients undergoing minor surgery were studied. Twenty-one patients were long-term treated (ACEI group), while the other patients served as controls (nonACEI group). All patients received a balanced electrolyte solution (6 ml kg(-1)) 20 min before spinal anaesthesia. RESULTS: Mean arterial blood pressure decreased 19% in both groups within 20 min after spinal anaesthesia. Heart rate did not change in either group. Plasma renin concentration increased from 7.3 +/- 2.1 to 12.8 +/- 4 pg ml(-1) during spinal anaesthesia in nonACEI patients (P < 0.05), whereas an elevated plasma renin level remained unchanged in the nonACEI group. The angiotensin II concentration increased in both groups during spinal anaesthesia (P < 0.05). The vasopressin concentration did not change during spinal anaesthesia in the ACEI group, but increased from 1.2 +/- 0.3 to 2.2 +/- 0.5 pg ml(-1) in patients with ACEI treatment (P < 0.05). The norepinephrine concentration increased transiently 5 min after spinal anaesthesia in both groups, and returned to baseline levels within 15 min. CONCLUSION: Long-term ACEI treatment does not further exaggerate the blood pressure decrease in the early phase of spinal anaesthesia. The increase in vasopressin concentrations in ACEI treated patients seems to be sufficient to compensate for the inhibited renin-angiotensin system. In addition, the transient increase in plasma norepinephrine, which occurs independent of preoperative ACEI treatment, seems to be involved in blood pressure regulation during spinal anaesthesia.
Asunto(s)
Anestesia Raquidea , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Presión Sanguínea/efectos de los fármacos , Anciano , Angiotensina II/sangre , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Epinefrina/sangre , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Norepinefrina/sangre , Concentración Osmolar , Renina/sangre , Factores de Tiempo , Vasopresinas/sangreRESUMEN
Acute hypoxia induces a decrease in plasma renin activity (PRA), mediated, e.g., by an increase in adenosine concentration, calcium channel activity, or inhibition of ATP-sensitive potassium channels. The decrease in PRA results in a decrease in angiotensin II (AngII) and plasma aldosterone concentration (PAC). This study investigates whether these hypoxia-induced mechanisms can be inhibited by the L-type voltage-dependent calcium channel antagonist nifedipine. Eight conscious, chronically tracheotomized dogs received a low sodium diet (0.5 mmol Na x kg body wt(-1) x day(-1)). The dogs were studied twice in randomized order, either with nifedipine infusion (1.5 microg x kg body wt(-1) x min(-1), Nifedipine) or without (Control). The dogs were breathing spontaneously: first hour, normoxia [inspiratory oxygen fraction (FiO2)=0.21]; second and third hour hypoxia (FiO2=0.1). In Controls, PRA (6.8+/-0.8 vs. 3.0+/-0.5 ngAngI x ml(-1) x min(-1)), AngII (13.3+/-1.9 vs. 7.3+/-1.9 pg/ml), and PAC (316+/-50 vs. 69+/-12 pg/ml) decreased during hypoxia (P<0.05). In Nifedipine experiments, PRA (6.5+/-0.9 vs. 10.5+/-2.4 ngAngI x ml(-1) x min(-1)) and AngII (14+/-1.1 vs. 18+/-3.9 pg/ml) increased during hypoxia, whereas the decrease in PAC (292+/-81 vs. 153+/-41 pg/ml) was blunted (P<0.05). These results foster the idea that the hypoxia-induced decrease in PRA involves L-type calcium channel activity.
Asunto(s)
Bloqueadores de los Canales de Calcio/farmacología , Hipoxia/sangre , Nifedipino/farmacología , Renina/sangre , Animales , Bloqueadores de los Canales de Calcio/uso terapéutico , Canales de Calcio Tipo L/fisiología , Estado de Conciencia/efectos de los fármacos , Estado de Conciencia/fisiología , Perros , Femenino , Hipoxia/tratamiento farmacológico , Nifedipino/uso terapéuticoRESUMEN
UNLABELLED: Hypoxic pulmonary vasoconstriction (HPV) is encountered during ascent to high altitude. Atrial natriuretic peptide (ANP) could be an option to treat HPV because of its natriuretic, diuretic, and vasodilatory properties. Data on effects of ANP on pulmonary and systemic circulation during HVP are conflicting, partly owing to anesthesia, surgical stress or uncontrolled dietary conditions. Therefore, ten conscious, chronically tracheotomized dogs were studied under standardized dietary conditions. The dogs were trained to breathe spontaneously at a ventilator circuit. PROTOCOL: 30min of normoxia [inspiratory oxygen fraction (F(i)O(2))=0.21] were followed by 30min of hypoxia without ANP infusion (Hypoxia I, F(i)O(2)=0.1). While maintaining hypoxia an intravenous infusion of atrial natriuretic peptide was started with 50ng x kg body wt(-1) x min(-1) for 30min (Hypoxia+ANP1=low dose), followed by 1000ng x kg body wt(-1) x min(-1) for 30min (Hypoxia+ANP2=high dose). Thereafter, ANP infusion was stopped and hypoxia maintained for a final 30min (Hypoxia II). Compared to normoxia, mean pulmonary arterial pressure (MPAP) (16+/-0.7 vs. 26+/-1.3mmHg) and pulmonary vascular resistance (PVR) (448+/-28 vs. 764+/-89dyn x s(-1) x cm(-5)) increased during Hypoxia I and decreased during Hypoxia+ANP 1 (MPAP 20+/-1mmHg, PVR 542+/-55dyn x s(-1) x cm(-5)) (P<0.05). The higher dose of ANP did not further decrease MPAP or PVR, but started to have a tendency to decrease mean arterial pressure and cardiac output. We conclude that low dose ANP is able to reduce HPV without affecting systemic circulation during acute hypoxia.
Asunto(s)
Factor Natriurético Atrial/farmacología , Circulación Sanguínea/fisiología , Hipoxia/tratamiento farmacológico , Circulación Pulmonar/efectos de los fármacos , Vasoconstricción/efectos de los fármacos , Angiotensina II/sangre , Animales , Factor Natriurético Atrial/farmacocinética , Análisis de los Gases de la Sangre , GMP Cíclico/sangre , Perros , Esquema de Medicación , Hemodinámica/efectos de los fármacos , Hemodinámica/fisiología , Concentración de Iones de Hidrógeno , Hipoxia/fisiopatología , Infusiones Intravenosas , Oxígeno/sangre , Arteria Pulmonar/efectos de los fármacos , Arteria Pulmonar/fisiopatología , Circulación Pulmonar/fisiología , Intercambio Gaseoso Pulmonar/fisiología , Renina/sangre , Factores de Tiempo , Resistencia Vascular/efectos de los fármacosRESUMEN
This study investigated whether adenosine mediates the decrease in plasma renin activity (PRA) during acute hypoxia. Eight chronically tracheotomized, conscious beagle dogs were kept under standardized environmental conditions and received a low-sodium diet (0.5 mmol.kg body wt(-1).day(-1)). During the experiments, the dogs were breathing spontaneously via a ventilator circuit: first hour, normoxia (21% inspiratory concentration of O(2)); second and third hours, hypoxia (10% inspiratory concentration of O(2)). Each of the eight dogs was studied twice in randomized order in control and theophylline experiments. In theophylline experiments, theophylline, an A(1)-receptor antagonist, was infused intravenously during hypoxia (loading dose: 3 mg/kg within 30 min, maintenance: 0.5 mg. kg(-1). h(-1)). In theophylline experiments, PRA (5.9 +/- 0.8 ng ANG I. ml(-1). h(-1)) and ANG II plasma concentration (15.9 +/- 2.3 pg/ml) did not decrease during hypoxia, whereas plasma aldosterone concentration decreased from 277 +/- 63 to 132 +/- 23 pg/ml (P < 0.05). In control experiments, PRA decreased from 6.8 +/- 0.8 during normoxia to 3.0 +/- 0.5 ng ANG I. ml(-1). h(-1) during hypoxia, ANG II decreased from 13.3 +/- 1.9 to 7.3 +/- 1.9 pg/ml, and plasma aldosterone concentration decreased from 316 +/- 50 to 70 +/- 13 pg/ml (P < 0.05). Thus infusion of the adenosine receptor antagonist theophylline inhibited the suppression of the renin-angiotensin system during acute hypoxia. The decrease in aldosterone occurred independently and is apparently directly related to hypoxia. In conclusion, it is likely that adenosine mediates the decrease in PRA during acute hypoxia in conscious dogs.
Asunto(s)
Hemodinámica/fisiología , Hipoxia/fisiopatología , Sistema Renina-Angiotensina/fisiología , Renina/sangre , Teofilina/farmacología , Enfermedad Aguda , Adenosina/fisiología , Aldosterona/sangre , Angiotensina I/sangre , Angiotensina II/sangre , Animales , Presión Sanguínea/efectos de los fármacos , Dióxido de Carbono/sangre , Estado de Conciencia , Dieta Hiposódica , Perros , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Hipoxia/sangre , Oxígeno/sangre , Presión Parcial , Potasio/sangre , Antagonistas de Receptores Purinérgicos P1 , Sistema Renina-Angiotensina/efectos de los fármacos , Teofilina/administración & dosificaciónRESUMEN
Angiotensin (ANG) II effects may be partly mediated by endothelin (ET)-1. This study analyses the hemodynamic, renal, and hormonal responses of acute ET(A) receptor antagonism (LU-135252) at two ANG II plasma levels in eight conscious dogs. Protocol 1 involved a 60-min baseline, followed by two doses of ANG II for 60 min each (4 and 20 ng. kg(-1). min(-1)), termed ANG II 4 (slightly increased) and ANG II 20 (pathophysiologically increased ANG II plasma concentration). Protocol 2 was the same as protocol 1 but included 15 mg/kg iv LU-135252 after the baseline period. Protocol 3 was a 3-h time control. ANG II without LU-135252 did not increase plasma big ET-1 and ET-1, whereas LU-135252 increased ET-1 transiently after injection. This transient ET-1 increase was not reflected in urinary ET-1 excretion. The ANG II induced decreases in sodium, water, and potassium excretion, glomerular filtration rate, and fractional sodium excretion were not different with and without LU-135252. Mean arterial pressure increased during ANG II and was not lower with LU-135252 (-6 mmHg, not significant). Most importantly, during ANG II 20 LU-135252 prevented the decrease in cardiac output. Simultaneously, systemic vascular resistance increased 40% less, pulmonary vascular resistance was maintained at baseline levels, and central venous and wedge pressure were lower. Because ANG II stimulated endothelin de novo synthesis should just have started after 2 h of ANG II infusion, there must be mechanisms other than blocking the coupling of de novo synthesized endothelins to the ET(A) receptors to explain the effects of acute ET(A) receptor inhibition in our setting.
Asunto(s)
Angiotensina II/sangre , Angiotensina II/farmacología , Antagonistas de los Receptores de Endotelina , Endotelina-1/sangre , Hemodinámica/fisiología , Fenilpropionatos/farmacología , Pirimidinas/farmacología , Urodinámica/fisiología , Aldosterona/sangre , Angiotensina II/administración & dosificación , Animales , Creatinina/metabolismo , Perros , Endotelina-1/orina , Endotelinas/orina , Femenino , Tasa de Filtración Glomerular/efectos de los fármacos , Tasa de Filtración Glomerular/fisiología , Hemodinámica/efectos de los fármacos , Infusiones Intravenosas , Inyecciones Intravenosas , Fenilpropionatos/administración & dosificación , Precursores de Proteínas/orina , Circulación Pulmonar/fisiología , Pirimidinas/administración & dosificación , Receptor de Endotelina A , Valores de Referencia , Renina/sangre , Sistema Renina-Angiotensina/efectos de los fármacos , Sistema Renina-Angiotensina/fisiología , Urodinámica/efectos de los fármacos , Resistencia Vascular/fisiologíaRESUMEN
OBJECTIVES: To study the effects of an inhaled endothelin A (ET(A)) receptor antagonist on hemodynamics and pulmonary gas exchange in experimental acute lung injury (ALI). DESIGN AND SETTING: Prospective, randomized, and controlled study in a university laboratory. PARTICIPANTS AND INTERVENTIONS: Sixteen pigs were ventilated in a volume controlled mode during general anesthesia. ALI was induced by surfactant depletion using repetitive lung lavages until the PaO2/FIO2 ratio was below 100 mmHg. The animals were then randomly assigned to receive either a nebulized ET(A) receptor antagonist (LU-135252, 3 mg/kg, inhaled over 1 h; LU group) or nebulization of saline (5-10 ml inhaled over 1 h) with no further intervention (controls). MEASUREMENTS AND RESULTS: Parameters of hemodynamics and gas exchange were measured for 6 h after induction of ALI. In the LU group intrapulmonary right-left shunting (QS/QT) decreased from 58 +/- 8% at the onset of ALI to 27 +/- 12% 3 h and 24 +/- 9% 6 h after ALI (p < 0.05); PaO2 increased from 55 +/- 12 to 257 +/- 148 mmHg 3 h and 270 +/- 136 mmHg 6 h after ALI. (p < 0.05), whereas in controls QS/QT and PaO2 did not improve over the 6 h after onset of ALI. In the LU group mean pulmonary artery pressure was stable for 6 h after ALI (26-29 mmHg), while in controls it increased from 28 +/- 2 to 41 +/- 2 mmHg (p < 0.05). Inhaled LU-135252 reduced cardiac output by 31 +/- 11% (p < 0.05) and increased systemic vascular resistance by 60 +/- 29 % (p < 0.05), while these parameters remained stable in controls. CONCLUSION: In this porcine model of ALI the inhalation of an ET(A) receptor antagonist improved arterial oxygenation and maintained a stable pulmonary artery pressure without inducing systemic vasodilatation.
Asunto(s)
Hemodinámica/efectos de los fármacos , Fenilpropionatos/farmacología , Intercambio Gaseoso Pulmonar/efectos de los fármacos , Pirimidinas/farmacología , Administración por Inhalación , Animales , Modelos Animales de Enfermedad , Humanos , Recién Nacido , Fenilpropionatos/administración & dosificación , Estudios Prospectivos , Pirimidinas/administración & dosificación , Síndrome de Dificultad Respiratoria del Recién Nacido/tratamiento farmacológico , Estadísticas no Paramétricas , PorcinosRESUMEN
Acute hypoxic pulmonary vasoconstriction (HPV) may be mediated by vasoactive peptides. We studied eight conscious, chronically tracheostomized dogs kept on a standardized dietary sodium intake. Normoxia (40 min) was followed by hypoxia (40 min, breathing 10% oxygen, arterial oxygen pressures 36 +/- 1 Torr) during both control (Con) and losartan experiments (Los; iv infusion of 100 microg. min-1. kg-1 losartan). During hypoxia, minute ventilation (by 0.9 l/min in Con, by 1.3 l/min in Los), cardiac output (by 0.36 l/min in Con, by 0.30 l/min in Los), heart rate (by 11 beats/min in Con, by 30 beats/min in Los), pulmonary artery pressure (by 9 mmHg in both protocols), and pulmonary vascular resistance (by 280 and 254 dyn. s. cm-5 in Con and Los, respectively) increased. Mean arterial pressure and systemic vascular resistance did not change. In Con, PRA decreased from 4.2 +/- 0.7 to 2.5 +/- 0.5 ng ANG I. ml-1. h-1, and plasma ANG II decreased from 11.9 +/- 3.0 to 8.2 +/- 2.1 pg/ml. The renin-angiotensin system is inhibited during acute hypoxia despite sympathetic activation. Under these conditions, ANG II AT1-receptor antagonism does not attenuate HPV.
Asunto(s)
Antihipertensivos/farmacología , Hipoxia/fisiopatología , Losartán/farmacología , Circulación Pulmonar/fisiología , Renina/sangre , Vasoconstricción/fisiología , Angiotensina II/sangre , Animales , Bicarbonatos/sangre , Análisis de los Gases de la Sangre , Presión Sanguínea/fisiología , Dieta , Perros , Femenino , Frecuencia Cardíaca/fisiología , Hemodinámica/fisiología , Hipoxia/sangre , Volumen Plasmático/fisiología , Mecánica Respiratoria/fisiología , Resistencia Vascular/fisiologíaRESUMEN
In 12 conscious dogs, we investigated whether the angiotensin II-receptor antagonist losartan increases renal sodium excretion and urine volume during controlled mechanical ventilation (CMV) with positive end-expiratory pressure. In four experimental protocols, the dogs were extracellular volume (ECV) expanded (electrolyte solution, 0.5 ml. kg-1. min-1 iv) or not and received losartan (100 micrograms. kg-1. min-1 iv) or not. They breathed spontaneously during the 1st and 4th hour and received CMV with positive end-expiratory pressure (mean airway pressure 20 cmH2O) during the 2nd and 3rd hours. In the expansion group, dogs with losartan excreted approximately 18% more sodium (69 +/- 7 vs. 38 +/- 5 micromol. min-1. kg-1) and 15% more urine during the 2 h of CMV because of a higher glomerular filtration rate (5.3 +/- 0.3 vs. 4.5 +/- 0.2 ml. min-1. kg-1) and the tubular effects of losartan. In the group without expansion, sodium excretion (2.0 +/- 0.6 vs. 2.6 +/- 1.0 micromol. min-1. kg-1) and glomerular filtration rate (3.8 +/- 0.3 vs. 3.8 +/- 0.4 ml. min-1. kg-1) did not change, and urine volume decreased similarly in both groups during CMV. Plasma vasopressin and aldosterone increased in both groups, and plasma renin activity increased from 4.9 +/- 0.7 to 7.8 +/- 1.3 ng ANG I. ml-1. h-1 during CMV in nonexpanded dogs without losartan. Mean arterial pressure decreased by 10 mmHg in nonexpanded dogs with losartan. In conclusion, losartan increases sodium excretion and urine volume during CMV if the ECV is expanded. If the ECV is not expanded, a decrease in mean arterial blood pressure and/or an increase in aldosterone and vasopressin during CMV attenuates the renal effects of losartan.